Six months after COVID-19 hit, one trend has emerged as a dominant theme: making virtual clinical trials a reality. 

Now, as you and your teams prepare to restart clinical trials, are you struggling with questions like:

• Am I sure we have a solid plan?
• Where should we plan to virtualize so we can start trials?
• How are we going to remain competitive?

This report delves deep into clinical operation leaders' plans at Sponsors and CROs to help you prioritize - and to invest - in virtual technology adoption.

In this report, you’ll discover:​ ​

• Where you should be investing in virtual tech so you aren't left behind.
• Major industry shifts, like the 75% of clinical operations leaders that now believe that PI meetings could be just as effective virtually.
• Where clinical operations leaders are planning to adopt virtual technology.​
• The new, post-COVID priorities for pharma and biotech leaders, like a new focus on-site readiness for 78% of clinical operations leaders.